Inhibikase Therapeutics Inc.

NASDAQ: IKT
Share price (12/20/24): $3.20
Market cap (12/20/24): $215 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Prospectus supplement

Shelf registration – amended

Shelf registration

Prospectus supplement

Initial registration of new securities

Ownership Filter

Armistice Capital, LLC

Soleus Private Equity Fund III, L.P.

SP IKT Holdings LLC

Sands Capital Life Sciences Pulse Fund II, L.P.

Sands Capital Ventures, LLC, Sands Frank M., Sands Capital Life Sciences Pulse Fund II, L.P.

News Filter

Termination of Material Definitive Agreement

Announces Closing of Up to $275 Million Financing and Advancement of IkT-001Pro Into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, Into a Late-Stage Trial in Pulmonary Arterial Hypertension

Investor Presentation

Shareholder Vote Results

Proxies Filter

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Other Filter

Notice of effectiveness

Statement regarding change in majority of directors

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC